JP2020535184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535184A5 JP2020535184A5 JP2020517843A JP2020517843A JP2020535184A5 JP 2020535184 A5 JP2020535184 A5 JP 2020535184A5 JP 2020517843 A JP2020517843 A JP 2020517843A JP 2020517843 A JP2020517843 A JP 2020517843A JP 2020535184 A5 JP2020535184 A5 JP 2020535184A5
- Authority
- JP
- Japan
- Prior art keywords
- expression vector
- human subject
- hvegf
- use according
- pyroglutamylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077454A JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564095P | 2017-09-27 | 2017-09-27 | |
| US62/564,095 | 2017-09-27 | ||
| US201762574657P | 2017-10-19 | 2017-10-19 | |
| US62/574,657 | 2017-10-19 | ||
| US201762579682P | 2017-10-31 | 2017-10-31 | |
| US62/579,682 | 2017-10-31 | ||
| US201862632812P | 2018-02-20 | 2018-02-20 | |
| US62/632,812 | 2018-02-20 | ||
| PCT/US2018/052855 WO2019067540A1 (en) | 2017-09-27 | 2018-09-26 | TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077454A Division JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535184A JP2020535184A (ja) | 2020-12-03 |
| JP2020535184A5 true JP2020535184A5 (enExample) | 2021-09-30 |
| JP7685833B2 JP7685833B2 (ja) | 2025-05-30 |
Family
ID=65903176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Active JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| JP2023077454A Pending JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077454A Pending JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200277364A1 (enExample) |
| EP (1) | EP3687464A4 (enExample) |
| JP (2) | JP7685833B2 (enExample) |
| KR (2) | KR20250040754A (enExample) |
| AU (2) | AU2018342094B2 (enExample) |
| CA (1) | CA3076905A1 (enExample) |
| IL (1) | IL273403A (enExample) |
| SG (1) | SG11202002396TA (enExample) |
| WO (1) | WO2019067540A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034963B1 (ru) | 2012-11-08 | 2020-04-13 | Клиасайд Байомедикал, Инк. | Способ лечения расстройства заднего сегмента глаза |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| IL262207B1 (en) | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| MY207644A (en) | 2017-12-19 | 2025-03-07 | Akouos Inc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US20220133908A1 (en) * | 2019-02-08 | 2022-05-05 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
| CN113966236A (zh) * | 2019-04-03 | 2022-01-21 | 再生生物股份有限公司 | 眼睛病状的基因疗法 |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| AU2020336314A1 (en) * | 2019-08-26 | 2022-04-07 | Regenxbio Inc. | Treatment of diabetic retinopathy with fully-human post-translationally modified anti-VEGF Fab |
| JP2022552262A (ja) | 2019-10-07 | 2022-12-15 | リジェネックスバイオ インコーポレイテッド | アデノ随伴ウイルスベクター医薬組成物および方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021188803A1 (en) * | 2020-03-19 | 2021-09-23 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
| BR112023001648A2 (pt) | 2020-07-27 | 2023-04-04 | Anjarium Biosciences Ag | Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo |
| EP4225381A1 (en) * | 2020-10-07 | 2023-08-16 | RegenxBio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| WO2022119839A1 (en) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| AU2022347792A1 (en) * | 2021-09-18 | 2024-05-02 | Skyline Therapeutics Limited | Aav for the gene therapy of wet-amd |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US20070202186A1 (en) * | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| AR076796A1 (es) * | 2009-05-28 | 2011-07-06 | Glaxo Group Ltd | Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento. |
| US9079953B2 (en) * | 2009-06-17 | 2015-07-14 | Abbvie Biotherapeutics Inc. | Anti-VEGF antibodies and their uses |
| EP2559443A1 (en) * | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| TWI702955B (zh) * | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ） |
| CA2922483A1 (en) * | 2013-09-11 | 2015-03-19 | Neurotech Usa, Inc. | Encapsulated cell therapy cartridge |
| US10064752B2 (en) * | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| JP2019501200A (ja) * | 2016-01-08 | 2019-01-17 | クリアサイド バイオメディカル，インコーポレイテッド | 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス |
| KR20240005973A (ko) * | 2016-04-15 | 2024-01-12 | 리젠엑스바이오 인크. | 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료 |
| IL262207B1 (en) * | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| WO2021188803A1 (en) * | 2020-03-19 | 2021-09-23 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
-
2018
- 2018-09-26 WO PCT/US2018/052855 patent/WO2019067540A1/en not_active Ceased
- 2018-09-26 SG SG11202002396TA patent/SG11202002396TA/en unknown
- 2018-09-26 EP EP18862872.1A patent/EP3687464A4/en active Pending
- 2018-09-26 KR KR1020257008245A patent/KR20250040754A/ko active Pending
- 2018-09-26 US US16/645,877 patent/US20200277364A1/en not_active Abandoned
- 2018-09-26 CA CA3076905A patent/CA3076905A1/en active Pending
- 2018-09-26 AU AU2018342094A patent/AU2018342094B2/en active Active
- 2018-09-26 JP JP2020517843A patent/JP7685833B2/ja active Active
- 2018-09-26 KR KR1020207011989A patent/KR20200060456A/ko not_active Ceased
-
2020
- 2020-03-18 IL IL273403A patent/IL273403A/en unknown
-
2023
- 2023-05-09 JP JP2023077454A patent/JP2023113641A/ja active Pending
- 2023-07-27 US US18/360,073 patent/US20240254214A1/en not_active Abandoned
-
2025
- 2025-02-26 US US19/064,049 patent/US20250320287A1/en active Pending
- 2025-05-02 AU AU2025203154A patent/AU2025203154A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535184A5 (enExample) | ||
| JP7544766B2 (ja) | 片頭痛の治療または予防法 | |
| US8758748B2 (en) | Anti-angiogenic therapy | |
| JP2010528047A5 (enExample) | ||
| AU2015204503B2 (en) | Novel vaccines against HPV and HPV-related diseases | |
| AU2017299581B2 (en) | Humanized monoclonal antibodies that target ve-ptp (hptp-β) | |
| CN109071656A (zh) | 检查点调节物拮抗剂 | |
| US20220162296A1 (en) | Personalized treatment of ophthalmologic diseases | |
| HUE032654T2 (en) | scFv antibodies that cross the epithelial and / or endothelial layers | |
| TW201726741A (zh) | Ctla4結合劑 | |
| CN107635580A (zh) | 治疗眼病的方法 | |
| WO2007120828A1 (en) | Use of il-i antibodies for treating ophthalmic disorders | |
| Touchard et al. | Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product | |
| KR102373289B1 (ko) | 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도 | |
| JP2018530574A5 (enExample) | ||
| KR20220002972A (ko) | 변형 항 pd-l1 항체 및 신경변성 질환 치료 방법 및 용도 | |
| CN102958536A (zh) | 用抗-vegf疗法治疗血管化色素上皮脱离 | |
| EP4419143A1 (en) | Methods of use and administration of encapsulated cells | |
| TW201806970A (zh) | 嵌合抗原受體、及其利用 | |
| JP2020518641A (ja) | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 | |
| JPWO2021041373A5 (enExample) | ||
| Matei et al. | What’s coming in therapies for diabetic retinopathy | |
| CN118791612A (zh) | 靶向cd26的抗原结合蛋白及其药物应用 | |
| CN118812720A (zh) | 靶向pdl1和cd3的双特异性抗体及其应用 | |
| Barakat et al. | Neovascular AMD: Where do we go from here? |